MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.

This long-term, prospective, randomised, head-to-head trial demonstrated a numerical trend for increased risk of MACE and VTE (only the 10 mg dose), among other serious adverse events, for the JAK inhibitor tofacitinib compared with TNF inhibitor therapy in a population enriched for CV risk (patients who were aged ≥50 years with at least one CV risk factor). 16 The increased relative ris

also in 337 other papers

In a post hoc analysis from this study, the 10 mg dose of tofacitinib showed a trend for increased risk of venous thromboembolism (VTE) compared with patients who were taking TNF inhibitor therapy among patients both with and without a history of atherosclerotic CV disease.

also in 18,965 other papers